Issledovanie effekta i deystviya liraglutida pri sakharnom diabete (LEADTM) Expert Rev. Endocrinol. Metab. 4(2), 119-129 (2009)
https://doi.org/10.14341/2072-0351-5809
Abstract
Лираглутид ? это первый аналог человеческого глюкагоноподобного пептида-1, основанный на структуре нативного глюкагоноподобного пептида-1. Фармакокинетические свойства препарата позволяют применять его один раз в день. В исследованиях II фазы и программе?Исследование эффекта и действия лираглутида при диабете (LEADTM)? III фазы, лираглутид стойко снижал уровень гликированного гемоглобина A1c. Лираглутид также улучшал функцию b-клеток, способствовал снижению массы тела и систолического артериального давления, а также позитивно влиял на некоторые маркеры сердечно-сосудистого риска. Лираглутид обладает хорошей переносимостью; наиболее распространенным побочным эффектом является транзиторная тошнота.В данной статье приведен обзор исследований II фазы и программы LEADTM III фазы.
References
1. Turner RC. The U.K. Prospective Diabetes Study. A review. Diabetes Care21 (Suppl. 3), C35–C38 (1998).
2. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sul- fonylurea, metformin, or insulin in patients with Type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospec- tive Diabetes Study (UKPDS) Group. JAMA 281 (21), 2005–2012 (1999).
3. Nauck M, Stockmann F, Ebert R, Creutzfeldt W. Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1), 46–52 (1986).
4. Vilsboll T, Holst JJ. Incretins, insulin secretion and Type 2 diabetes melli- tus. Diabetologia 47 (3), 357–366 (2004).
5. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glu- cose-stimulated insulin secretion: effects on -cell sensitivity in Type 2 and nondiabetic subjects. Diabetes 52(2), 380–386 (2003).
6. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroente- rology 132 (6), 2131–2157 (2007).
7. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and -cell function in Type 2 diabetes: a parallel-group study. Lancet359 (9309), 824–830 (2002).
8. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of dia- betes: estimates for the year 2000 and projections for 2030. Diabetes Care27(5),1047–1053 (2004).
9. Bolen S, Feldman L, Vassy J et al. Systematic review: comparative effecti- veness and safety of oral medications for Type 2 diabetes mellitus. Ann. Intern. Med.147(6), 386–399 (2007).
10. Nathan DM, Buse JB, Davidson MB et al. Medical management of hy- perglycemia in Type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Dia- betes Association and the European Association for the Study of Diabe- tes. Diabetes Care32(1), 193–203 (2009).
11. Kahn SE, Haffner SM, Heise MA et al. Glycemic durability of rosiglita- zone, metformin, or glyburide monotherapy. N. Engl. J. Med.355(23),2427–2443 (2006).
12. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in Type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2), 194–206 (2007).
13. Madsbad S, Krarup T, Deacon CF, Holst JJ. Glucagon-like peptide re- ceptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr. Opin. Clin. Nutr. Metab. Care11 (4), 491–499 (2008).
14. Richter B, Bandeira-Echtler E, Bergerhoff K, Lerch CL. Dipeptidyl pepti- dase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Data- base Syst. Rev. (2), CD006739 (2008).
15. Bloomgarden ZT, Dodis R, Viscoli CM, Holmboe ES, Inzucchi SE. Lower baseline glycemia reduces apparent oral agent glucose-lowering effi- cacy: a meta-regression analysis. Diabetes Care 29(9), 2137–2139 (2006).
16. Agerso H, Vicini P. Pharmacodynamics of NN2211, a novel long acting GLP-1 derivative. Eur. J. Pharm. Sci.19(2–3),141–150 (2003).
17. Damholt B, Golor G, Wierich W, Pedersen P, Ekblom M, Zdravkovic M. An open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-analogue liraglutide. J. Clin. Pharmacol.46 (6), 635–641 (2006).
18. Nauck MA, Heimesaat MM, Behle K et al. Effects of glucagon-like pep- tide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J. Clin. Endocrinol. Metab.87(3),1239–1246 (2002).
19. Zdravkovic M, Ekblom M, Brondsted L, Vouis J, Lennerns H, Malm-Erje- falt M. The effect of liraglutide on the absorption phamacokinetics of con- comitant oral drugs with different solubility and permeability properties in healthy subjects. Diabetologia51,S355 (2008).
20. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Impro- ved glycemic control with no weight increase in patients with Type 2 dia- betes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, ran- domized, controlled trial. Diabetes Care 27(6), 1335–1342 (2004).
21. Feinglos MN, Saad MF, Pi-Sunyer FX, An B, Santiago O. Effects of lira- glutide (NN2211), a long-acting GLP-1 analogue, on glycaemic control and bodyweight in subjects with Type 2 diabetes. Diabet. Med.22 (8), 1016–1023 (2005).
22. Harder H, Nielsen L, Tu DT, Astrup A. The effect of liraglutide, a long-ac- ting glucagon-like peptide 1 derivative, on glycemic control, body com- position, and 24-h energy expenditure in patients with Type 2 diabetes. Diabetes Care27 (8), 1915–1921 (2004).
23. Nauck MA, Hompesch M, Filipczak R, Le TD, Zdravkovic M, Gumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with Type 2 diabe- tes. Exp. Clin. Endocrinol. Diabetes114(8),417–423 (2006).
24. Vilsboll T, Zdravkovic M, Le-Thi T et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly im- proves glycemic control and lowers body weight without risk of hypogly- cemia in patients with Type 2 diabetes. Diabetes Care30(6),1608–1610 (2007).
25. Vilsboll T, Brock B, Perrild H et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic -cell function and arginine-stimulated in- sulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet. Med.25 (2), 152–156 (2008).
26. Courreges JP, Vilsboll T, Zdravkovic M et al. Beneficial effects of once- daily liraglutide, a human glucagon-like peptide-1 analogue, on cardio- vascular risk biomarkers in patients with Type 2 diabetes. Diabet. Med.25 (9), 1129–1131 (2008).
27. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monot- herapy for Type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, Phase III, double-blind, parallel-treatment trial. Lancet 373 (9662), 473–481 (2009).
28. Marre M, Show J, Brändle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic control and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet. Med. (2009) (In press).
29. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in Type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32 (1), 84–90 (2009).
30. Zinman B, Gerich J, Buse J et al. Effect of the GLP-1 analog liraglutide on glycemic control and weight reduction in patients on metformin and rosi- glitazone: a randomized double-blind placebo-controlled trial. Diabeto- logia, 51 (Suppl. 1), S359 (2007) (Abstract 898).
31. Russell-Jones D, Vaag A, Schmitz O et al. Significantly better glycemic control and weight reduction with liraglutide, a once-daily human GLP-1 analog, compared with insulin glargine: all as add-on to metformin and a sulfonylurea in Type 2 diabetes. Diabetes 57, A159–A160 (2008).
32. Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. Initiation of insulin glargine therapy in Type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes. Metab.10 (5), 387–399 (2008).
33. Blonde L, Rosenstock J, Sesti G et al. Liraglutide: superior glycemic con- trol vs exenatide when added to metformin and/or SU in Type 2 diabe- tes. Presented at: Canadian Diabetes Association Annual General Meeting. Montréal, QB, Canada, 16 October 2008.
34. Nauck M, Brandle M, Vaag A et al. The once-daily human GLP-1 analog liraglutide substantially reduces HbA(1c) in subjects with Type 2 diabe- tes, irrespective of HbA(1c) at baseline. Diabetes 57, A594 (2008).
35. Russell-Jones D, Shaw JE, Brandle M et al. The once-daily human GLP-1 analog liraglutide reduces body weight in subjects with Type 2 diabetes, irrespective of body mass index at baseline. Diabetes 57, A593–A594 (2008).
36. Colagiuri S, Frid A, Zdravkovic M, Le-Thi TD, Vaag A. The once-daily human GLP-1 analog-liraglutide reduces systolic blood pressure in pa- tients with Type 2 diabetes. Diabetes57, A164–A165 (2008).
37. Matthews D, Marre M, Le-Thl TUD, Zdravkovic M, Simo R. Liraglutide, a once-daily human GLP-1 analog, significantly improves -cell function in subjects with Type 2 diabetes. Diabetes 57, A150–A151 (2008).
38. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur. J. Pharmacol.434 (3), 163–167 (2002).
39. Davis SN, Johns D, Maggs D, Xu H, Northrup JH, Brodows RG. Explo- ring the substitution of exenatide for insulin in patients with Type 2 diabe- tes treated with insulin in combination with oral antidiabetes agents. Diabetes Care 30 (11), 2767–2772 (2007).
Review
For citations:
Medsbed S. Issledovanie effekta i deystviya liraglutida pri sakharnom diabete (LEADTM) Expert Rev. Endocrinol. Metab. 4(2), 119-129 (2009). Diabetes mellitus. 2009;12(5):11-20. (In Russ.) https://doi.org/10.14341/2072-0351-5809
Views:
2556
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
